ENETS Research and Studies

ENETS encourages and supports non-commercial, multi-centric NET-related research within the ENETS community and the ENETS Centers of Excellence (CoE). This approach enables projects to collect the high-quality data required to answer clinical or translational questions in optimal timeframe.

Aims at a glance:

  • To increase collaboration within NET Centers/ ENETS CoE
  • To achieve a reliable amount of data answering NEN relevant scientific questions
  • To accelerate recruiting in prospective and retrospective clinical trials
  • To involve young researchers in collaborative research.

Below you will find information about current research projects and studies.

SurvivApp Study

ENETS is proud to announce the publication of the ENETS-endorsed SurvivApp study, titled “Hemicolectomy versus Appendectomy for Patients with Appendiceal Neuroendocrine Tumours 1–2 cm in Size: A Retrospective, Europe-wide, Pooled Cohort Study” in Lancet Oncology.

We congratulate and thank everyone involved in this important research and are delighted to have supported this significant initiative.

Read the article at The Lancet Oncolody

ASPEN trial publication

NEWS: ENETS is pleased to announce that the first interim analysis results from the ASPEN trial have been published British Journal of Surgery in late August 2022. Click below to read this open access article.

ENETS congratulates and thanks all those who have been working on this trial and is delighted to have been able to extend its support.

Read the publication

ENETS-supported Trials

ASPEN Study

Project title: "Asymptomatic Small Pancreatic Endocrine Neoplasms" The aim of the study is to evaluate the most appropriate management of sporadic asymptomatic non-functioning pancreatic neuroendocrine neoplasms (NF-PNEN) ≤ 2 cm. P NF-PNEN management will be decided at the hospital and all therapeutics decision will be decided/coordinated by the treating physician. Patients will be either submitted to surgical resection or to active surveillance. Principal Investigator: IRCCS San Raffaele Hospital, Massimo Falconi
learn more

SEQTOR

Project title: "Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)" (SEQTOR) The ongoing trial (SEQTOR) is currently investigating the antiproliferative efficacy and safety of everolimus, followed by STZ/5‐FU in advanced pancreatic NET (pNET) in a crossover design upon progression. Principal investigator: Medical Oncology Department, Duran i Reynals, Moisès Broggi & Costa de Ponent Hospitals, Institut Català d´Oncologia. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Ramon Salazar
learn more

ENETS-endorsed Trials

There are no items matching your search.

Institutional Collaborative Trials

There are no items matching your search.

Trials Supported by ENETS Grants

There are no items matching your search.